• Regulatory Outlook in Diagnostics Innovative and Uncertain

    Clinical Research News | The diagnostics industry is at the intersection of enormous clinical development and technological change, enabling first-ever detection milestones heavily driven by artificial intelligence and multi-biomarker tests. But it has increasingly been coming into conflict with a decades-old regulatory system that didn’t anticipate these technological changes and a political environment that favors U.S. competition and innovation but is also interested in cutting the budget.

    Jun 4, 2026

  • A ‘Credit-Score-Like’ Risk Assessment System for Investigative Drugs

    Clinical Research News | VeriSIM Life is building the “full-stack predictive infrastructure” to help pharma companies foresee the challenges ahead in translating a molecule from laboratory discovery to a successful human therapy. The help comes in the form of a dynamic, “credit-score-like” assessment of the risk with inherent explainability and trust.

    Jun 3, 2026

  • Phesi Highlights Disconnect Between Protocols and Outcomes, Warns of AI Repetition

    Clinical Research News | An analysis released by Phesi suggests that the systematic use of historical protocol templates without using patient data and context to guide protocol design leads to flaws being scaled, rather than solved, by AI.

    Jun 2, 2026

  • Flatiron’s AI-Powered Platform, Verana Health Ovarian Cancer Database, Eir Partners Invests in QuartzBio

    Clinical Research News | uMotif launches its new Scientific Consulting Services; Veeva Systems announces Veeva Falcon; b.well Connected Health and myTomorrows announce a partnership; and more.

    May 29, 2026

  • Insider Views on the FDA’s Evolving Relationship with AI

    Clinical Research News | The Food and Drug Administration is undergoing a major step change in how it regulates and evaluates drugs, marked by a shift toward real-time clinical trials, an agency-wide rollout of generative AI tools to speed up drug application reviews, and a radical transparency push that includes public disclosure of complete response letters sent to pharmaceutical companies explaining why a drug application was rejected.

    May 27, 2026